DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1M — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1M maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1m is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
From 1978 to 1992, a follow-up of 235 patients aged 16–70 with dilated cardiomyopathy found that two-year survival rose from 73.8% in the earliest period (1978–1982) to 90.3% in the latest (1988–1992), and four-year survival from 53.8% to 82.9%. The authors attributed part of this improvement to patients being younger and less severely affected at enrolment, but after stratifying for disease severity the survival difference remained significant, suggesting treatment effects. A progressively higher proportion of patients received ACE inhibitors and later beta blockers. In the middle period, patients treated with ACE inhibitors showed better survival than those not treated, after stratification for heart failure severity. In the latest period, beta blockers had a significant additive effect with conventional therapy: four-year survival in mild and moderate-to-severe heart failure patients treated with beta blockers (usually with digitalis and ACE inhibitors) was 90% and 87.5% respectively.
A 1991 review states that dilated cardiomyopathy is the most common form of cardiomyopathy, defined anatomically by large chambers, thin or normal walls, and poor systolic function. In the United States, up to 10,000 deaths per year were attributed to cardiomyopathy, 80% of them the dilated form. The review covers aetiologies, mechanisms, pathophysiology, diagnostic approaches, clinical findings, prognosis, and therapy, but provides no new survival data.
A 2025 study of 200 patients divided into three age groups examines age-related features of diagnosis and treatment of dilated cardiomyopathy. It highlights echocardiographic parameters, laboratory findings, and modern therapeutic strategies, with attention to individualisation based on age and comorbidities. No survival or response rates are reported.
What is still missing is prospective trial data that isolates the effect of any single drug class from the confounding effects of earlier diagnosis and changing patient characteristics. No randomised controlled trial comparing modern combination therapy against placebo or older regimens in a contemporary, well-characterised cohort is presented. The 2025 study does not report outcomes, so the question of whether survival has continued to improve since the 1990s remains unanswered. Stratification by genetic subtype, aetiology, or sex is absent from all three abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Heart · 1994 · 76 citations · open access
Changing mortality in dilated cardiomyopathy
AbstractOBJECTIVE: To analyse the changes in mortality in dilated cardiomyopathy over the past 15 years and to identify the factors that might have influenced survival. DESIGN: Follow up study of 235 patients (aged 16-70) systematically enrolled on a register from 1 January 1978 to 31 December 1992. SETTING: Hospital department of cardiology. PATIENTS: Three groups corresponding to three periods of 5 years: group 1 (diagnosis between 1 January 1978 and 31 December 1982) 26 patients; group 2 (diagnosis between 1 January 1983 and 31 December 1987) 65 patients; and group 3 (diagnosis between 1 January 1988 and 31 December 1992) 144 patients. MAIN OUTCOME MEASURES: Death or heart transplantation. RESULTS: Two and four year survival was 73.8% and 53.8% in group 1, 87.7% and 72.3% in group 2, and 90.3% and 82.9% in group 3 (P = 0.02). During the 15 years of the study period the number of cases increased progressively and the baseline clinical characteristics changed (that is, patients were younger and less severely affected), partly explaining the improvement in survival. None the less, the three mortality curves tended to diverge progressively and the improvement in survival in the different groups was still significant after stratification for the severity of the disease, suggesting that treatment had a sustained effect. A progressively higher proportion of patients were treated with angiotensin converting enzyme (ACE) inhibitors and more recently with beta blockers. In group 2, after stratification for the severity of heart failure, patients who were treated with ACE inhibitors showed a better survival than patients who were not. Furthermore, analysis of group 3 showed that beta blockers had a significant additive effect with conventional therapy both by intention to treat and actual treatment. Four year survival in patients with mild and moderate to severe heart failure treated with beta blockers, and usually digitalis and ACE inhibitors, was respectively 90% and 87.5%. CONCLUSIONS: The improvement in the survival of patients with dilated cardiomyopathy over the past 15 years may be explained by earlier diagnosis, new treatments, and a change in the clinical characteristics of the patients at enrolment.
Current Opinion in Cardiology · 1991 · 1 citations
Dilated cardiomyopathy
AbstractDilated cardiomyopathy is the most common form of cardiomyopathy and is anatomically defined by large atrial and ventricular chambers, thin or normal myocardial walls, and poor systolic function. In the United States, up to 10,000 deaths every year have been determined to be secondary to cardiomyopathy, and of these 80% were due to the dilated form of the disease. This review describes recent advances of DCM, which can be grouped into the following headings: 1)etiologies and mechanisms of disease; 2) pathophysiology of the dilated heart; 3) diagnostic approaches; 4) clinical findings and prognosis; and 5) therapy.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
DILATED CARDIOMYOPATHY IN PATIENTS OF DIFFERENT AGE GROUPS DIAGNOSTIC AND TREATMENT FEATURES
AbstractDilated cardiomyopathy (DCM) is a severe myocardial disorder characterized by progressive dilation and dysfunction of the left ventricle, ultimately leading to heart failure. This article examines the age-related features of the manifestation, diagnosis, and treatment of DCM. The study is based on an analysis of data from 200 patients divided into three age groups. Key diagnostic markers are highlighted, including echocardiographic parameters and laboratory findings, as well as specific treatment approaches utilizing modern therapeutic strategies. Particular attention is paid to the individualization of treatment based on age and the presence of comorbidities.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
